Related Experiment Video
Updated: Jan 26, 2026

Virus Delivery of CRISPR Guides to the Murine Prostate for Gene Alteration
Published on: April 27, 2018
A novel CRISPR-engineered prostate cancer cell line defines the AR-V transcriptome and identifies PARP inhibitor
Evangelia Kounatidou1, Sirintra Nakjang1, Stuart R C McCracken1
1Northern Institute for Cancer Research, Newcastle University, Paul O'Gorman Building, Framlington Place, Newcastle Upon Tyne, NE2 4HH, UK.
Abstract:
Resistance to androgen receptor (AR)-targeted therapies in prostate cancer (PC) is a major clinical problem. A key mechanism of treatment resistance in advanced PC is the generation of alternatively spliced forms of the AR termed AR variants (AR-Vs) that are refractory to targeted agents and drive tumour progression. Our understanding of how AR-Vs function is limited due to difficulties in distinguishing their discriminate activities from full-length AR (FL-AR). Here we report the development of a novel CRISPR-derived cell line which is a derivative of CWR22Rv1 cells, called CWR22Rv1-AR-EK, that has lost expression of FL-AR, but retains all endogenous AR-Vs. From this, we show that AR-Vs act unhindered by loss of FL-AR to drive cell growth and expression of androgenic genes. Global transcriptomics demonstrate that AR-Vs drive expression of a cohort of DNA damage response genes and depletion of AR-Vs sensitises cells to ionising radiation. Moreover, we demonstrate that AR-Vs interact with PARP1 and PARP2 and are dependent upon their catalytic function for transcriptional activation. Importantly, PARP blockade compromises expression of AR-V-target genes and reduces growth of CRPC cell lines suggesting a synthetic lethality relationship between AR-Vs and PARP, advocating the use of PARP inhibitors in AR-V positive PC.
Insights
Androgen receptor variants (AR-Vs) drive prostate cancer growth and resistance to therapy. Targeting PARP in AR-V positive cancers shows promise for synthetic lethality, offering new treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Prostate cancer (PC) resistance to androgen receptor (AR)-targeted therapies is a significant clinical challenge.
- Tumor progression in advanced PC is driven by AR variants (AR-Vs), which are resistant to current treatments.
- Distinguishing AR-V activity from full-length AR (FL-AR) has been difficult, limiting understanding of their function.
Purpose of the Study:
- To develop a model system to isolate the function of AR-Vs from FL-AR.
- To investigate the role of AR-Vs in driving tumor growth and gene expression.
- To identify therapeutic vulnerabilities associated with AR-V activity.
Main Methods:
- Development of a novel CRISPR-derived cell line (CWR22Rv1-AR-EK) lacking FL-AR but retaining AR-Vs.
- Global transcriptomics to analyze gene expression changes driven by AR-Vs.
- Investigation of AR-V interactions with DNA damage response proteins, specifically PARP1 and PARP2.
Main Results:
- AR-Vs independently drive cell growth and androgenic gene expression in the absence of FL-AR.
- AR-Vs upregulate a set of DNA damage response genes, and their depletion sensitizes cells to ionizing radiation.
- AR-Vs interact with and depend on PARP1 and PARP2 for transcriptional activity.
Conclusions:
- AR-Vs are key drivers of treatment resistance and tumor progression in prostate cancer.
- A synthetic lethality exists between AR-Vs and PARP, suggesting a therapeutic strategy.
- PARP inhibitors show potential for treating AR-V positive castration-resistant prostate cancer (CRPC).
Related Concept Videos
CRISPR
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
What is Genetic Engineering?
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Defining Psychology
Defining Social Psychology

